Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
US12372536B2 · kind B2 · utility
0Cited by
3References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 28, 2022 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Dec 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.